Trial reportCirculation2021
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.
Trial report in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 4 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Comparative effectiveness of statins, metformin, and vitamin D, for prevention of preeclampsia: a systematic review and network meta-analysis of randomized trials.BMC pregnancy and childbirth · 2026Pooled it
- The role of statins during pregnancy on maternal risk of preeclampsia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Pravastatin in preeclampsia: A meta-analysis and systematic review.Frontiers in medicine · 2022Pooled it
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Role of a Heart Center for Women in the Prevention and Diagnosis of Atherosclerotic Cardiovascular Disease in Women.Journal of the American Heart Association · 2026Review
- Preeclampsia trials that changed practice.Seminars in perinatology · 2026Review
- Screening for Term Preeclampsia at 35 to 37 Weeks of Gestation: A Single-Center Experience.Fetal diagnosis and therapy · 2026Article
- Lipid Profile and Management of Dyslipidemias in Pregnancy.Journal of cardiovascular development and disease · 2025Review
- Pravastatin and L-Arginine Use in Early-Onset Severely Growth-Restricted Dichorionic Twins: A Case Report.The American journal of case reports · 2025Article
- Beyond LDL Cholesterol Reduction: Pleiotropic Profiling of Statins.Current atherosclerosis reports · 2025Review
- Multi-omic insights of preeclampsia and cardiovascular health outcomes.Communications medicine · 2025Review
- The human placenta and its role in reproductive outcomes revisited.Physiological reviews · 2025Review
- Prediction of Small for Gestational Age and Growth-Restricted Neonates at 35 to 36 Weeks of Gestation: A Multicenter Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Antioxidants: powering the fight against fetal hypoxia.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- B Cell Tolerance and Obstetric Antiphospholipid Syndrome.Clinical reviews in allergy & immunology · 2025Review
- Heme oxygenase/carbon monoxide system affects the placenta and preeclampsia.Medical gas research · 2025Review
- Maternal Calcium Intake at 36 Weeks' Gestation and Pre-Eclampsia Risk-A Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2025Article
- Association of D-dimer, platelet-activating factor, and soluble vascular endothelial growth factor receptor 1 levels with disease severity and prognosis in gestational hypertension.American journal of translational research · 2025Article
- Identification of Coagulation and Fibrinolysis-Associated Biomarkers With Implications for Preeclampsia.Genetics research · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 13 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease.
methodsIn this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1120 women with singleton pregnancies at high risk of term preeclampsia to receive pravastatin at a dose of 20 mg/d or placebo from 35 to 37 weeks of gestation until delivery or 41 weeks. The primary outcome was delivery with preeclampsia at any time after randomization. The analysis was performed according to intention to treat.
resultsA total of 29 women withdrew consent during the trial. Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Allowing for the effect of risk at the time of screening and participating center, the mixed-effects Cox regression showed no evidence of an effect of pravastatin (hazard ratio for statin/placebo, 1.08 [95% CI, 0.78-1.49];
conclusionsPravastatin in women at high risk of term preeclampsia did not reduce the incidence of delivery with preeclampsia. Registration: URL: https://www.isrctn.com; Unique identifier ISRCTN16123934.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.